Gabapentin Capsule
Product Images NDC 71610-072

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-072). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 100 mg (71610 0072 60)

Gabapentin 100 mg oral capsules label showing a 90 capsule count. The label includes storage instructions, manufacturer information listing Watson Pharma Private Limited in Verna, India, and repackager Aphena Pharma Solutions - Tennessee, LLC. It features the NDC 71610-0072-60 with barcodes and states 'RX Only.'*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

1 (Image 1)

A text panel showing a medical formula for calculating creatinine clearance (CLCr). The formula accounts for age, weight, sex, and serum creatinine levels. It is displayed in a mathematical expression format typically used for clinical reference.*

FDA Label Image

1 (Image 10)

Gabapentin 100 mg oral capsules bottle label from Aphena Pharma Solutions - Tennessee, LLC. The amber plastic bottle displays the product name, dosage strength, dosage form, and labeler. The label shows a white background with black and blue text and a child-resistant cap on the bottle.*

FDA Label Image

1 (Image 11)

Gabapentin 100 mg oral capsules by Aphena Pharma Solutions - Tennessee, LLC. The white capsule is shown against a black background. The image displays a single capsule with no other text or packaging visible.*

FDA Label Image

1 (Image 12)

Gabapentin 100 mg oral capsules in a blister pack. The blister contains 14 white and gray hard capsules arranged in two rows of seven. The packaging shows the Aphena Pharma Solutions - Tennessee, LLC labeler information and NDC 71610-072.*

FDA Label Image

1 (Image 2)

Gabapentin 100 mg oral capsules packaging label from Aphena Pharma Solutions - Tennessee, LLC. The label features the product name Gabapentin and strength 100 mg prominently, with multiple capsules shown in a circular arrangement, highlighting the capsule dosage form.*

FDA Label Image

1 (Image 3)

Gabapentin 100 mg oral capsule packaging label by Aphena Pharma Solutions - Tennessee, LLC. The image shows a single orange and white capsule on a plain white background, matching the specified 100 mg strength.*

FDA Label Image

1 (Image 4)

Gabapentin 100 mg oral capsules in a clear plastic blister pack. The capsules are white to off-white with no visible imprint. This packaging is labeled for Aphena Pharma Solutions - Tennessee, LLC and includes a total of 14 capsules arranged in two rows of seven.*

FDA Label Image

1 (Image 5)

Chemical structure diagram of gabapentin showing its cyclohexane ring bonded to an aminomethyl group and an acetic acid group. The image depicts the molecular arrangement of gabapentin, the active ingredient in the product.*

FDA Label Image

1 (Image 6)

A line graph showing mean pain scores over 8 weeks comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period, while the y-axis represents mean pain score. Gabapentin group shows a decreasing pain score trend, while placebo remains relatively stable.*

FDA Label Image

2 (Image 7)

A line graph depicting mean pain scores over a 7-week period for placebo and two dosages of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 10. The graph shows decreasing pain scores for both Gabapentin groups compared to placebo.*

FDA Label Image

3 (Image 8)

A bar chart comparing percentages for two studies labeled Study 1 and Study 2. Study 1 displays percentages for PBO and GBP 3600 groups, while Study 2 shows PBO, GBP 1800, and GBP 2400 groups. Significance levels are noted with double and triple asterisks indicating p-values less than 0.01 and 0.001, respectively.*

FDA Label Image

4 (Image 9)

A scatter plot comparing percentage differences across daily doses of 600 mg, 900 mg, 1200 mg, and 1800 mg for three studies labeled a, b, and c. The y-axis represents the difference (%) ranging from 2 to 22, and the x-axis represents daily dose in milligrams. Study a is marked in black, study b in gray, and study c in white, each showing different percentage differences at the indicated doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.